Lag­gard Lil­ly says its CDK 4/6 drug abe­maci­clib scored in PhI­II, while ri­vals at No­var­tis, Pfiz­er sharp­en their knives

Just a week af­ter No­var­tis scored a key ap­proval for its CDK 4/6 can­cer drug, Eli Lil­ly is an­nounc­ing that its long-await­ed Phase III read­out for its ri­val drug abe­maci­clib looks good. We won’t get the da­ta un­til lat­er, but the phar­ma gi­ant says its MONARCH-2 tri­al comes with pos­i­tive pro­gres­sion-free da­ta on ad­vanced hor­mone-re­cep­tor-pos­i­tive, HER2 neg­a­tive breast can­cer.

In­ves­ti­ga­tors com­pared abe­maci­clib com­bined with ful­ves­trant to ful­ves­trant alone. And the da­ta set up an FDA fil­ing some­time in the next three months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.